CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Segment Expenditure Addition To Long Lived Assets
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) reported Segment Expenditure Addition To Long Lived Assets of $31.11 million for the 3-month period ending 2026-06-27, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Segment Reporting
us-gaap:SegmentExpenditureAdditionToLongLivedAssets · last filed 2026-08-05
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. segment expenditure addition to long lived assets for the quarter ending 2026-06-27 was $31.11M, a 11.88% decline year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. segment expenditure addition to long lived assets for the quarter ending 2025-06-28 was $35.30M.
| Period end | Segment Expenditure Addition To Long Lived Assets 3 month | Segment Expenditure Addition To Long Lived Assets 6 month |
|---|---|---|
| 2026-06-27 | $31.11M 10-Q · filed 2026-08-05 | $87.01M 10-Q · filed 2026-08-05 |
| 2025-06-28 | $35.30M 10-Q · filed 2026-08-05 | $94.62M 10-Q · filed 2026-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |